Belimumab
- Generic Name
- Belimumab
- Brand Names
- Benlysta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 356547-88-1
- Unique Ingredient Identifier
- 73B0K5S26A
- Background
Belimumab is a fully human recombinant IgG1λ monoclonal antibody that inhibits soluble human B lymphocyte stimulator protein (BLyS, also referred to as BAFF and TNFSF13B), a B cell survival factor. BLyS levels are often elevated in immunodeficient and autoimmune disorders, such as systemic lupus erythematosus (SLE). By binding to BLyS and blocking its intera...
- Indication
In the US, belimumab is indicated to treat active systemic lupus erythematosus (SLE) and active lupus nephritis in patients aged five years and older who are receiving standard therapy. In Europe, belimumab is also used to treat SLE and lupus nephritis but only in adults.
...
- Associated Conditions
- Active Systemic Lupus Erythematosus, Lupus Nephritis
- Associated Therapies
- -
BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115
- First Posted Date
- 2012-05-14
- Last Posted Date
- 2020-03-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 142
- Registration Number
- NCT01597622
- Locations
- 🇰🇷
GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of
A Study of Belimumab in the Prevention of Kidney Transplant Rejection
- First Posted Date
- 2012-02-22
- Last Posted Date
- 2017-04-25
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 30
- Registration Number
- NCT01536379
- Locations
- 🇬🇧
GSK Investigational Site, London, United Kingdom
Belimumab (BENLYSTA®) Pregnancy Registry
- First Posted Date
- 2012-02-14
- Last Posted Date
- 2023-01-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 77
- Registration Number
- NCT01532310
- Locations
- 🇨🇭
GSK Investigational Site, Zürich, Switzerland
A Study to Investigate Belimumab for the Treatment of Chronic Immune Thrombocytopenia.
- Conditions
- Interventions
- First Posted Date
- 2011-09-26
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT01440361
GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia
- First Posted Date
- 2011-05-02
- Last Posted Date
- 2019-10-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 709
- Registration Number
- NCT01345253
- Locations
- 🇰🇷
GSK Investigational Site, Suwon, Kyonggi-do, Korea, Republic of
Efficacy and Safety of Belimumab in Subjects With Primary Sjögren's Syndrome
- First Posted Date
- 2010-07-12
- Last Posted Date
- 2012-07-03
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 20
- Registration Number
- NCT01160666
- Locations
- 🇫🇷
Assistance Publique - Hôpitaux de Paris : BICETRE Hospital, Le Kremlin Bicêtre, France
A Study of Belimumab in Treating Symptomatic Waldenstroms Macroglobulinaemia
- First Posted Date
- 2010-06-11
- Last Posted Date
- 2012-02-10
- Lead Sponsor
- Cancer Trials Australia
- Target Recruit Count
- 15
- Registration Number
- NCT01142011
- Locations
- 🇦🇺
The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺Alfred Health, Melbourne, Victoria, Australia
Desensitization With Belimumab in Sensitized Patients Awaiting Kidney Transplant
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 8
- Registration Number
- NCT01025193
- Locations
- 🇺🇸
University of Pennsyvlania Kidney Transplant Program, Philadelphia, Pennsylvania, United States
Expanded Access Trial of Belimumab Antibody in RA Patients Who Were Previously Treated Under HGS Protocol LBRA99
- Conditions
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2012-10-31
- Lead Sponsor
- Human Genome Sciences Inc., a GSK Company
- Registration Number
- NCT00931086
- Locations
- 🇺🇸
Rheumatology Associates of Central Florida, Orlando, Florida, United States
A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057
- First Posted Date
- 2008-07-10
- Last Posted Date
- 2019-12-05
- Lead Sponsor
- Human Genome Sciences Inc., a GSK Company
- Target Recruit Count
- 738
- Registration Number
- NCT00712933
- Locations
- 🇬🇧
GSK Investigational Site, Newcastle Upon Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.